{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.1","value":"237"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.1","value":"244"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.7","value":"255"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Day 169"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"description":"Serum concentration at end of infusion (CEOI) of Avelumab is reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part B: Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Analysis Set included all participants who received at least 1 dose of avelumab, and provided at least 1 measurable post-dose concentration. Here \"Number analyzed\" signifies those participants who were evaluable at specified time-point for this outcome measure.","reportingStatus":"POSTED","timeFrame":"At Day 1, 43 and 169","title":"Part B: Serum Concentration at End of Infusion (CEOI) of Avelumab","type":"SECONDARY","unitOfMeasure":"Microgram per milliliter"}